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Abstract 
Objective: To evaluate the effect of rusovastatin on the clinical disease activity index(CDAI) and health 
assessment questionnaire disability index(HAQ-DI) in rheumatoid arthritis patients(RA). 
Methods: A single center randomized double-blind placebo-controlled trial of 8 weeks duration was performed. 
Patients had RA according to the 1987 American College of Rheumatology (ACR) criteria. Disease activity was 
measured by CDAI and functional disability by HAQ-DI. They were treated by rusovastatin 10mg tablet or 
identical placebo (PBO). 
Results: Of 74 randomly assigned patients, 40 completed 8 weeks. Twenty from the rosuvastatin group and 20 
from the PBO. No significant difference between the change of CDAI produced by rusovastatin compared to that 
of PBO after 8weeks (-45.95±42.14 (-30.87%) versus -26.15±48.05 (-19.03%), p= 0.174) although it was 
clinically relevant. Also no statistical significant difference between the change of HAQDI produced by 
rusovastatin compared to that of PBO after 8weeks (-0.48±0.40 (-27.74%) versus -0.36±0.36 (-22.09%), p= 
0.477). 
Conclusions: Rusovastatin has no statistical significant effect on CDAI and HAQDI, however clinically may be 
relevant. Large long prospective study is needed. 
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1. Introduction 
Rheumatoid arthritis is a chronic systemic inflammatory disease of unknown etiology characterized by articular 
involvement and extra articular involvement [1]. Additionally it is a progressive disease that cause damage and 
disability [2,3]. 
Many studies have reported an increased risk of mortality in patients with RA [4-6]. So the primary 
goal of treating the patient with rheumatoid arthritis is to maximize long-term health-related quality of life which 
can be achieved through reduction of inflammation; Moreover treatment to target by measuring disease activity 
and adjusting therapy accordingly optimizes outcomes in RA [7]. Clinical disease activity index CDAI is a 
purely clinical score and it is a valid measure of disease activity with greatest merits in clinical practice rather 
than research, since it may facilitate immediate and consistent treatment decisions and help in improving patient 
outcomes in the longer term [8]. Whereas Health assessment questionnaire – disability index (HAQ-DI) is very 
responsive to change, and usually is the most sensitive to change of the available outcome measures [9] 
Rosuvastatin is a unique HMGCoA reductase inhibitor that used to treat dyslipidemia [10]. It also 
exerts important anti-inflammatory effects in addition to its lipid-lowering actions [11].This study was designed 
to evaluate the possible benefit of low dose rosuvastatin on RA disease activity (CDAI) and patient functional 
disability(HAQDI). 
 
2. Methods 
2.1 Study design 
This was an 8-week randomized double blind placebo-controlled single center study conducted at Rheumatology 
Unit, Baghdad Teaching Hospital, Baghdad, Iraq from August 2011 till May 2012. Patients were randomly 
allocated to receive each day either rosuvastatin 10mg tablet or capsule prefilled with glucose as placebo (PBO). 
Rosuvastatin was bought from Unipharma Company, Syria whereas glucose was bought from SDI, Iraq. Patients 
were evaluated at baseline and at week 8. 
Informed consent was obtained from all participants and this study was approved by the ethical 
committee of Baghdad University, College of Medicine - Medical Department. 
2.2 Sample selection 
Eligible patients had confirmed RA according to the 1987 American College of Rheumatology (ACR) criteria 
with moderate to highly active disease defined as CDAI greater than 11 at baseline. For inclusion, patients also 
were required to have taken methotrexate (MTX) regularly for at least 3 previous consecutive months. The 
exclusion criteria included patients who were taking lipid-lowering therapy, had hypersensitivity to statin, 
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pregnancy, breast feeding, renal and liver impairment, patients younger than 18 years old and those using high 
dose steroids. 
2.3 Clinical evaluation 
Clinical evaluation of patients for tender and swelling joints was done by specialized rheumatologist who was 
blinded to treatment at zero time (baseline) and after 8 weeks.  
RA disease activity was measured using CDAI which was calculated by simple summation of tender and 
swelling joint count, visual analogue scale (VAS) as stated by the patient (VAS) and physician or evaluator 
(EGA) [8] , whereas functional disability was measured by HAQDI [9]. 
2.4 Statistical analysis 
Statistical software (SPSS v. 12, Chicago, IL, USA) was used for data input and analysis. Continuous variables 
were presented as mean ± standard deviation (SD) and discrete variables were presented as frequencies and 
percentages. Chi square test for independence was used to test the significance of association between discrete 
variables. Continuous variables were tested by a web version of Shapiro Wilk test to determine if they were 
normally or abnormally distributed.  
       Paired T test was used to test the significance of difference in means of pre and post treatment in normally 
distributed continuous variables.   
       Unpaired T test was used to test the significance of difference in the mean of two independent samples in 
normally distributed continuous variables and Mann Whitney test for abnormally distributed data.  
 All P values used were asymptotic and two sided. Findings with P value less than 0.05 were considered 
significant whereas P values less than 0.01 considered highly significant. Statistical power was not calculated 
since it is a pilot study. 
 
3. Results 
Of 74 patients randomized in this double-blind study, 40 completed the 8weeks of treatment (20 from the 
rosuvastatin group and 20 from the PBO). The two groups did not differ significantly in the baseline 
characteristics (Table 1). 
After 8 weeks of treatment, rosuvastatin reduced very highly significantly CDAI while placebo reduced 
CDAI significantly .Also, both rosuvastatin and placebo reduced very highly significantly HAQDI score (Table 
2, 3) 
However, there was no statistical significant difference between the effect of rusovastatin and placebo 
on CDAI and HAQDI (p>0.05, table 4).  
 
Table1: Baseline characteristics of 76 RA patients 
Parameter Rosuvastatin Placebo P 
Age, years 43.35 ± 9.96 44.4 ± 13.53 0.781 
Female: Male Ratio 14:6 (70%) 16:4 (80%) 0.465 
Disease duration, years 7.55  ±  5.38 6.65 ±  4.96 0.586 
Dose of MTX, mg 13.88±  4.40 13.25 ± 3.54 0.624 
Family Hx of +ve RA 2 (10%) 7 (35%) 0.058 
Positive RF n (%) 13 (65%) 12 (60%) 0.743 
Sc nodule n (%) 2 (10%) 0 (0%) 0.147 
CDAI 149.6±45.79 137.45±47.63 0.416 
HAQDI 1.73± 0.74 1.63±0.65 0.633 
 
   Data are mean±SD;  n, number; %, percentile; Sc, subcutaneous; CDAI, clinical disease activity index; 
HAQDI, health assessment questionnaire disability index. P> 0.05 not significant 
 
Table2: Effect of treatment on CDAI 
Group      CDAI  
 Pre-treatment 
(at   Baseline) 
    CDAI 
 Post-treatment 
(After 8weeks)  
Change 
(Percent of change) 
P value 
Rosuva-
statin 
149.6±45.79 103.65±58.12  -45.95±42.14 
(-30.87%) 
 0.000* 
Placebo 137.45±47.63 111.3±47.69 -26.15±48.05 
(-19.03%) 
0.025** 
Data are mean ±SD; *p<0.01, highly significant;** p<0.05,  significant; CDAI, clinical disease activity index. 
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Table3: Effect of treatment on HAQDI 
  
Data are mean±SD; HAQDI, health assessment questionnaire disability index; *p<0.01, highly significant. 
 
Table 4: Comparison of the change produced in CDAI and HAQDI after 8 weeks of treatment 
Parameter Rosuvastatin Placebo P value 
CDAI -45.95±42.14 -26.15±48.05 0.174 
HAQDI -0.48±0.40 -0.36±0.36 0.477 
   Data are mean±SD; CDAI, clinical disease activity index; HAQDI, health assessment questionnaire disability 
index. P> 0.05 not significant 
 
4. Discussion 
Approaches to management of RA disease activity, functional capacity, and outcome have evolved because of 
the availability of an increasing number of effective disease-modifying anti-rheumatic drugs (DMARDs) 
[12].Assessing RA disease activity regularly is a very important aspect in the management but this aspect is 
often neglected. Recently, CDAI has come up for assessing the disease activity [13]. It is simple, completely 
clinical score, and easy to calculate. Hence, it is possible to determine the disease activity immediately in a 
physician’s chamber especially when a patient visits for the first time or turns non-compliant to the laboratory 
investigations advised, which is so common in this chronic disease. Additionally, HAQ-DI, a type of patient 
reported outcome, has become an established approach to assess health outcomes in RA patients [14].  
This study showed that the reduction of CDAI in RA patients after 8 weeks of treatment with rosuvastatin was 
clinically relevant compared to that by placebo (-45.95±42.14 versus -26.15±48.05), however the effect was 
statistically not significant. 
According to the current evaluation of the literature, there were  no other studies (in addition to the 
current one) that focus on the effect of statin on RA disease activity as measured by CDAI and it is the 1
st
 time to 
get such result,  but instead there were 2 other studies examining the effect of rosuvastatin on RA disease activity 
by disease activity score of 28 joints (DAS28) [15,16], the results of these studies showed that rosuvastatin was 
not able to significantly reduce RA disease activity when compared to placebo, which agreed with the finding of 
this study since there is a direct and positive correlation between DAS28 and CDAI as shown in other clinical 
studies [17,18].    
Moreover rosuvastatin was no more effective than placebo to reduce HAQDI score. Similar finding was 
reported by Kumar et al who studied the effects of rosuvastatin on  RA patients  in a pilot randomized double-
blind placebo-controlled trial conducted on 50 patients from rheumatology clinics throughout Tayside in 
Scotland. [15] where they found rusovastatin does not improve the overall rheumatoid disease activity including 
HAQDI [15]. 
The absence of statistical significant improvement in both disease activity and functional ability by rosuvastatin 
may be attributed to the small sample size and to the use of low dose of rusovastatin. Ghaisas et al [19] reported 
that there was a dose-dependent antioxidant, analgesic, and anti-inflammatory activities of rosuvastatin.  
The small sample of the study, short period of follow up, and small dose of the rusovastatin used might be a 
limitation of this study. However, this may be improved and solved by a large, long duration prospective study 
with higher doses of rusovastatin. 
 
5. Conclusions 
Rosuvastatin has no statistical significant effect on disease activity and functional disability in active RA patients 
although it was clinically relevant. This may suggest that rusovastatin can be beneficial and may be used as 
adjuvant therapy to other medications for treatment of RA. A large  long prospective study is  needed. 
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